OBJECTIVE： To investigate the compliance and its influential factors of endocrine drug therapy in patients with Luminal breast cancer， and to provide reference in clinic. METHODS： A total of 257 patients with Luminal breast cancer were selected from our hospital during Jun. 1st， 2009-May 31st， 2012. General information questionnaire combined with Morisky therapy compliance scale were used for survey during telephone follow-up or outpatient review. Single factor analysis and multiple factors Logistic regression analysis were conducted for the influential factors of endocrine drug therapy compliance. RESULTS： During the follow-up period， 22 patients died， and 17 patients lost follow-up； 218 patients completed 5 years of follow-up. The medieation rate of endocrine drug therapy was decreased with time. A total of 202 patients （92.7％） persisted in taking medicine for more than 1 year， 184 patients （84.4％） for more than 2 years， 172 patients （78.9％） for more than 3 years， 158 patients （72.5％） for more than 4 years and 138 patients （63.3％） for 5 years. Univariate analysis showed that the compliance of endocrine drug therapy was influenced by patients’ age， monthly income per capita， level of education， marital status， type of residence and with or without internal medicine complication （P＜0.05）. Logistic regression analysis showed that patients’ age， monthly income per capita， level of education， marital status were independent influential factors for the compliance of endocrine drug therapy. CONCLUSIONS： The medieation rate of endocrine drug therapy in patients with Luminal breast cancer is decreased with time. The patients’ age， monthly income per capita， level of education， marital status are independent factors for the compliance of endocrine drug therapy. Therefore， it is suggested to provide individualized， continuous and dynamic therapy plan according to patients’ condition， strengthen medication guidance and education， so as to improve the compliance of endocrine drug therapy.